Benralizumab, a monoclonal  antibody that targets the alpha receptor of IL-5, is effective in reducing severe asthma exacerbations and significantly reducing exacerbation-related resource utilisation and medical costs, confirms a recent study published in the Annals of Allergy, Asthma and Immunology. The research analysed 204 asthmatic patients with two or more records of benralizumab prescription and two or more exacerbation episodes with history of using AstraZeneca’s Fasenra. The study observed a 48 percent reduction in symptoms among inpatient cases, 53 percent in ED cases and 59 percent in outpatient cases and 41.2 percent patients having no exacerbation episodes during the post-index at all.